Sotera Health Q1 net rev up 12.5% to $248M; Adj EBITDA up 13.7%; reaffirms 2024 outlook

Sotera Health Co

2024-Q1 EPS reported $0.02 revenue$248,176,000

Q1 net rev $248M (+12.5% YoY); net income $6M ($0.02 EPS) vs $3M ($0.01) YoY.
Adj EBITDA $112M (+13.7% YoY); Adj EPS $0.13 flat YoY.
Sterigenics segment net rev $166M (+4.1% YoY); segment income $86M (+3.6%).
Company reaffirms 2024 outlook amid market headwinds.
EPA finalized NESHAP update; Sterigenics expects to comply with emission control investments.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.97

Sotera Health Co reported three months ended March 31, 2024 results: revenue $248 million, net income $6 million, or $0.02 per diluted share, EPS $0.02 per diluted share. Guidance reaffirmed.

Period: three months ended March 31, 2024
Revenue: $248 million
Net income: $6 million, or $0.02 per diluted share
EPS: $0.02 per diluted share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Sotera Health Reports First-Quarter 2024 Results • Q1 2024 net revenues increased 12.5% to $248 million, compared to Q1 2023 • Q1 2024 net income of $6 million or $0.02 per diluted share, comp ared to net income of $3 million or $0.01 per diluted share in Q1 2023 • Q1 2024 Adjusted

View on SEC.gov

222 earnings releases filed in the last 30 days. Browse all earnings releases →

Sotera Health Co filing history →

Source: SEC EDGAR

accession 0001822479-24-000015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.